Big Pharma Spends on Share Buybacks, but R&D? Not So Much

By Gretchen Morgenson

July 14, 2017

“Under fire for skyrocketing drug prices, pharmaceutical companies often offer this response: The high costs of their products are justified because the proceeds generate money for crucial research on new cures and treatments.”…

[Click HERE to read the full article]